Mark C. McKenna

Companies

• Helix Acquisition Corp. IIIBoard member Jan 22, 2026 to now¹
• NewAmsterdam Pharma Co N.V.Board member Jul 19, 2024 to now²
• Aeglea BioTherapeuticsBoard member Feb 5, 2024 to now³
• Apogee Therapeutics, Inc.Board member Aug 21, 2023 to now⁴
• Freenome, Inc.Board member Jun 11, 2024 to Jun 11, 2024⁵
• BridgeBio Oncology Therapeutics, Inc.Board member Feb 8, 2024 to Feb 8, 2024⁶
• Prometheus Biosciences, Inc.Chair Nov 16, 2021 to Jun 16, 2023⁷
• Prometheus Biosciences, Inc.Chief executive officer Mar 11, 2021 to Jun 16, 2023⁸
• Prometheus Biosciences, Inc.President Mar 11, 2021 to Jun 16, 2023⁸
• Prometheus Biosciences, Inc.Board member Mar 11, 2021 to Mar 11, 2021⁸
• Bausch HealthPresident Aug 10, 2018 to Aug 21, 2019⁹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• FFreenome, Inc. FRNM30,000 shares¹⁰$369.8K at $12.32Jul 20, 2026
• NPNewAmsterdam Pharma Co N.V. NAMS10,360 shares¹¹$210.2K at $20.29Jan 7, 2026
• BOBridgeBio Oncology Therapeutics, Inc. BBOT30,000 shares¹²$84.2K at $2.81Aug 11, 2025
• PBPrometheus Biosciences, Inc.0 shares¹³Jun 16, 2023
• ATApogee Therapeutics, Inc.0 shares¹⁴Sep 3, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Sep 3, 2026Returned to company 20,000 shares of Apogee Therapeutics, Inc.¹⁴
• Jul 20, 2026Converted 30,000 shares of Freenome, Inc.¹⁰
• Jan 7, 2026Granted 3,400 shares of NewAmsterdam Pharma Co N.V.¹¹
• Aug 11, 2025Exercised options 30,000 shares of BridgeBio Oncology Therapeutics, Inc.¹²
• Jan 7, 2025Granted 6,960 shares of NewAmsterdam Pharma Co N.V.¹⁵
• Dec 12, 2024Bought 12,500 shares at $49.85 of Apogee Therapeutics, Inc.¹⁶
• Dec 12, 2024Bought 7,500 shares at $49.02 of Apogee Therapeutics, Inc.¹⁶
• Jun 16, 2023Returned to company 178,098 shares of Prometheus Biosciences, Inc.¹³
• Jun 2, 2023Exercised options 3 shares at $1.70 of Prometheus Biosciences, Inc.¹⁷
• Jun 2, 2023Exercised options 122,528 shares at $2.90 of Prometheus Biosciences, Inc.¹⁷
• Mar 15, 2023Sold 25,000 shares at $116.14 of Prometheus Biosciences, Inc.¹⁸
• Mar 15, 2023Exercised options 25,000 shares at $2.90 of Prometheus Biosciences, Inc.¹⁸
• Mar 3, 2023Sold 10,620 shares at $125.13 of Prometheus Biosciences, Inc.¹⁹
• Mar 3, 2023Exercised options 10,620 shares at $3.70 of Prometheus Biosciences, Inc.¹⁹
• Mar 1, 2023Sold 700 shares at $125.26 of Prometheus Biosciences, Inc.¹⁹
• Mar 1, 2023Exercised options 700 shares at $3.70 of Prometheus Biosciences, Inc.¹⁹
• Feb 17, 2023Sold 13,680 shares at $125.10 of Prometheus Biosciences, Inc.²⁰
• Feb 17, 2023Exercised options 13,680 shares at $3.70 of Prometheus Biosciences, Inc.²⁰
• Feb 16, 2023Sold 25,000 shares at $119.87 of Prometheus Biosciences, Inc.²⁰
• Feb 16, 2023Exercised options 25,000 shares at $3.70 of Prometheus Biosciences, Inc.²⁰
• Feb 15, 2023Sold 25,000 shares at $119.42 of Prometheus Biosciences, Inc.²⁰
• Feb 15, 2023Exercised options 25,000 shares at $2.90 of Prometheus Biosciences, Inc.²⁰
• Jan 17, 2023Sold 25,000 shares at $118.99 of Prometheus Biosciences, Inc.²¹
• Jan 17, 2023Exercised options 25,000 shares at $2.90 of Prometheus Biosciences, Inc.²¹
• Dec 9, 2022Granted 37,113 shares of Prometheus Biosciences, Inc.²²